Project cooperationUpdated on 11 December 2025

Antion Biosciences: Gene Engineering Solutions

Scientist at Antion Biosciences

Plan-Les-Ouates, Switzerland

About

Antion's gene engineering technology is available for collaborative projects seeking to achieve ambitious goals. Antion's proprietary gene engineering technology offers key highlights:

A gene silencing platform with exceptional multiplexing capabilities.

Ability to simultaneously modify multiple genetic targets within a single cell, and co-expressing molecules of interest (ex: a CAR).

Precise tuning of target gene expression levels, highly versatile and applicable in a variety of settings and cell types, autologous or allogeneic therapy, cell and gene therapy, applicable for ex-vivo and in-vivo delivery methods.

Presents a highly favorable safety profile compared to gene editing approaches.

Topic

DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

Partner seeks Consortium/Coordinator

Organisation

Antion Biosciences

Company (SME)

Geneva, Switzerland

Similar opportunities

Project cooperation
Allogeneic Cell therapy of cancer an autoimmune diseases
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Cristina Maccalli
Principal Investigator at IRCCS Azienda Ospedaliera Metropolitana, plesso Ospedale Policlinico San Martino
Genova, Italy
Project cooperation
Advanced Nanoparticle Platforms for Targeted Therapeutics and Gene Delivery
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Paola Astolfi
Associate professor at Università Politecnica delle Marche
Ancona, Italy
Project cooperation
B-cell mediated immune responses in health and disease.
- Partner seeks Consortium/Coordinator
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Lesly Calderon
Principal Investigator at Helmholtz Munich and TUM
Munich, Germany